Coenzyme Q10 Supplementation

Coenzyme Q10 Supplementation

• Intervention
  In patients with heart failure (NYHA Classes I-IV/AHA Stages B and C), what is the effect of Coenzyme Q10 supplementation on quality of life, signs and symptoms?

  • Conclusion
    In patients with heart failure (NYHA Classes I–IV/AHA Stages B and C), research reported mixed results regarding the effect of Coenzyme Q10 supplementation on quality of life, signs and symptoms. One study reported that the group receiving 150mg per day of oral Coenzyme Q10 had a significant improvement of 0.5 units in NYHA functional class after three months compared to the placebo group, which had no significant change. One study reported that 75% of study subjects reported no change in symptoms. However, due to the interactions between Coenzyme Q10 and some common heart-failure medications (warfarin, statins and beta-blockers), it is unclear whether this dose and duration of Coenzyme Q10 would be appropriate for patients with heart failure. Research is needed regarding the effect of Coenzyme Q10 supplementation on quality of life in patients with heart failure.
  • Grade: III
    • Grade I means there is Good/Strong evidence supporting the statement;
    • Grade II is Fair;
    • Grade III is Limited/Weak;
    • Grade IV is Expert Opinion Only;
    • Grade V is Not Assignable.
    • High (A) means we are very confident that the true effect lies close to that of the estimate of the effect;
    • Moderate (B) means we are moderately confident in the effect estimate;
    • Low (C) means our confidence in the effect estimate is limited;
    • Very Low (D) means we have very little confidence in the effect estimate.
    • Ungraded means a grade is not assignable.
  • Evidence Summary: In patients with heart failure (NYHA Classes I–IV/AHA Stages B and C), what is the effect of coenzyme Q10 supplementation on quality of life, signs and symptoms?
    • Detail
    • Quality Rating Summary
      For a summary of the Quality Rating results, click here.
    • Worksheets
      • Keogh A, Fenton S, Leslie C, Aboyoun C, Macdonald P, Zhao Y, Bailey M, Rosenfeldt F. Randomised double-blind, placebo-controlled trial of coenzyme Q, therapy in class II and III systolic heart failure. Heart, Lung & Circulation 2003; 12:135-41
  • Search Plan and Results: HF: Supplements (2014)
     
  In patients with heart failure (NYHA Classes I–IV/AHA Stages B and C), what is the effect of Coenzyme Q10 supplementation on quality measures (re-admissions rate, length of stay, mortality)?

  • Conclusion
    In patients with heart failure (NYHA Classes I–IV/AHA Stages B and C), research reported no hospital admissions or deaths during the three-month intervention period within or between groups receiving either 150mg per day of oral Coenzyme Q10 or placebo. However, due to the interactions between Coenzyme Q10 and some common heart-failure medications (warfarin, statins and beta-blockers), it is unclear whether this dose and duration of Coenzyme Q10 would be appropriate for patients with heart failure. Research is needed regarding the effect of Coenzyme Q10 supplementation on quality measures in patients with heart failure.
  • Grade: III
    • Grade I means there is Good/Strong evidence supporting the statement;
    • Grade II is Fair;
    • Grade III is Limited/Weak;
    • Grade IV is Expert Opinion Only;
    • Grade V is Not Assignable.
    • High (A) means we are very confident that the true effect lies close to that of the estimate of the effect;
    • Moderate (B) means we are moderately confident in the effect estimate;
    • Low (C) means our confidence in the effect estimate is limited;
    • Very Low (D) means we have very little confidence in the effect estimate.
    • Ungraded means a grade is not assignable.
  • Evidence Summary: In patients with heart failure (NYHA Classes I to IV/AHA Stages B and C), what is the effect of coenzyme Q10 supplementation on quality measures (re-admissions rate, length of stay, mortality)?
    • Detail
    • Quality Rating Summary
      For a summary of the Quality Rating results, click here.
    • Worksheets
      • Keogh A, Fenton S, Leslie C, Aboyoun C, Macdonald P, Zhao Y, Bailey M, Rosenfeldt F. Randomised double-blind, placebo-controlled trial of coenzyme Q, therapy in class II and III systolic heart failure. Heart, Lung & Circulation 2003; 12:135-41
  • Search Plan and Results: HF: Supplements (2014)
     
  In patients with heart failure (NYHA Classes I–IV/AHA Stages B and C), what is the effect of Coenzyme Q10 supplementation on renal function labs and clinical labs?

  • Conclusion
    In patients with heart failure (NYHA Classes I–IV/AHA Stages B and C), research reported no significant differences in creatinine levels after three months within or between groups receiving either 150mg per day of oral Coenzyme Q10 or placebo. Research is needed regarding the effect of Coenzyme Q10 supplementation on BUN, BNP and serum sodium in patients with heart failure.
  • Grade: III
    • Grade I means there is Good/Strong evidence supporting the statement;
    • Grade II is Fair;
    • Grade III is Limited/Weak;
    • Grade IV is Expert Opinion Only;
    • Grade V is Not Assignable.
    • High (A) means we are very confident that the true effect lies close to that of the estimate of the effect;
    • Moderate (B) means we are moderately confident in the effect estimate;
    • Low (C) means our confidence in the effect estimate is limited;
    • Very Low (D) means we have very little confidence in the effect estimate.
    • Ungraded means a grade is not assignable.
  • Evidence Summary: In patients with heart failure (NYHA Classes I to IV/AHA Stages B and C), what is the effect of coenzyme Q10 supplementation on renal function labs and clinical labs?
    • Detail
    • Quality Rating Summary
      For a summary of the Quality Rating results, click here.
    • Worksheets
      • Keogh A, Fenton S, Leslie C, Aboyoun C, Macdonald P, Zhao Y, Bailey M, Rosenfeldt F. Randomised double-blind, placebo-controlled trial of coenzyme Q, therapy in class II and III systolic heart failure. Heart, Lung & Circulation 2003; 12:135-41
  • Search Plan and Results: HF: Supplements (2014)
     
  In patients with advanced heart failure (NYHA Class IV/AHA Stage D), what is the effect of Coenzyme Q10 supplementation on quality measures (re-admissions rate, length of stay, mortality)?

  • Conclusion
    In patients with advanced heart failure (NYHA Class IV/AHA Stage D), there were no studies identified that reported on the effect of Coenzyme Q10 supplementation on quality measures.
  • Grade: V
    • Grade I means there is Good/Strong evidence supporting the statement;
    • Grade II is Fair;
    • Grade III is Limited/Weak;
    • Grade IV is Expert Opinion Only;
    • Grade V is Not Assignable.
    • High (A) means we are very confident that the true effect lies close to that of the estimate of the effect;
    • Moderate (B) means we are moderately confident in the effect estimate;
    • Low (C) means our confidence in the effect estimate is limited;
    • Very Low (D) means we have very little confidence in the effect estimate.
    • Ungraded means a grade is not assignable.
  • Search Plan and Results: HF: Supplements (2014)
     
  In patients with advanced heart failure (NYHA Class IV/AHA Stage D), what is the effect of Coenzyme Q10 supplementation on quality of life, signs and symptoms?

  • Conclusion
    In patients with advanced heart failure (NYHA Class IV/AHA Stage D), research reported that patients with end-stage heart failure awaiting cardiac transplantation receiving 60mg per U per day of Ultrasome-CoQ10 for three months had improved quality of life and significant decreases in frequency of nocturia, severity of fatigue, severity in dyspnea and NYHA functional classification, compared to those receiving placebo. However, due to the interactions between Coenzyme Q10 and some common heart-failure medications (warfarin, statins and beta-blockers), it is unclear whether this dose and duration of Coenzyme Q10 would be appropriate for patients with advanced heart failure. Further research is needed regarding the effect of Coenzyme Q10 supplementation on quality of life, signs and symptoms.
  • Grade: III
    • Grade I means there is Good/Strong evidence supporting the statement;
    • Grade II is Fair;
    • Grade III is Limited/Weak;
    • Grade IV is Expert Opinion Only;
    • Grade V is Not Assignable.
    • High (A) means we are very confident that the true effect lies close to that of the estimate of the effect;
    • Moderate (B) means we are moderately confident in the effect estimate;
    • Low (C) means our confidence in the effect estimate is limited;
    • Very Low (D) means we have very little confidence in the effect estimate.
    • Ungraded means a grade is not assignable.
  • Evidence Summary: In patients with advanced heart failure (NYHA Class IV/AHA Stage D), what is the effect of coenzyme Q10 supplementation on quality of life, signs and symptoms?
    • Detail
  • Search Plan and Results: HF: Supplements (2014)
     
  In patients with advanced heart failure (NYHA Class IV/AHA Stage D), what is the effect of Coenzyme Q10 supplementation on renal function labs and clinical labs?

  • Conclusion
    In patients with advanced heart failure (NYHA Class IV/AHA Stage D), there were no studies identified that reported on the effect of Coenzyme Q10 supplementation on renal function labs and clinical labs.
  • Grade: V
    • Grade I means there is Good/Strong evidence supporting the statement;
    • Grade II is Fair;
    • Grade III is Limited/Weak;
    • Grade IV is Expert Opinion Only;
    • Grade V is Not Assignable.
    • High (A) means we are very confident that the true effect lies close to that of the estimate of the effect;
    • Moderate (B) means we are moderately confident in the effect estimate;
    • Low (C) means our confidence in the effect estimate is limited;
    • Very Low (D) means we have very little confidence in the effect estimate.
    • Ungraded means a grade is not assignable.
  • Search Plan and Results: HF: Supplements (2014)